Financials Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 21/05/2024 BST 5-day change 1st Jan Change
149.6 USD -0.41% Intraday chart for Alnylam Pharmaceuticals, Inc. +1.17% -21.83%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 12,840 15,100 20,282 29,238 24,021 18,926 - -
Enterprise Value (EV) 1 12,293 13,417 18,522 28,132 23,979 17,663 18,451 17,448
P/E ratio -14.2 x -17.4 x -23.6 x -25.6 x -54.4 x -42.3 x -80.3 x 81.1 x
Yield - - - - - - - -
Capitalization / Revenue 58.4 x 30.6 x 24 x 28.2 x 13.1 x 10.1 x 8.38 x 6.3 x
EV / Revenue 55.9 x 27.2 x 21.9 x 27.1 x 13.1 x 9.44 x 8.17 x 5.81 x
EV / EBITDA -13.9 x -16.9 x -28 x -38 x - -55.3 x 3,815 x 22.6 x
EV / FCF -29.4 x -19.6 x -25.8 x -45.9 x 572 x -55.6 x -2,028 x 25.4 x
FCF Yield -3.41% -5.11% -3.88% -2.18% 0.17% -1.8% -0.05% 3.94%
Price to Book 8.98 x 14.9 x 34.6 x -186 x -109 x -120 x -71.7 x 235 x
Nbr of stocks (in thousands) 111,490 116,181 119,601 123,028 125,493 126,492 - -
Reference price 2 115.2 130.0 169.6 237.6 191.4 149.6 149.6 149.6
Announcement Date 06/02/20 11/02/21 10/02/22 23/02/23 15/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 219.8 492.9 844.3 1,037 1,828 1,872 2,259 3,005
EBITDA 1 -885.1 -793.7 -661.1 -740.6 - -319.5 4.836 770.6
EBIT 1 -939.4 -828.4 -708.7 -785.1 -282.2 -371.6 -194.4 302.3
Operating Margin -427.5% -168.09% -83.93% -75.68% -15.43% -19.85% -8.61% 10.06%
Earnings before Tax (EBT) 1 -885.3 -855.6 -852.1 -1,127 -433.5 -475.5 -285.5 212.3
Net income 1 -886.1 -858.3 -852.8 -1,131 -440.2 -450.8 -256.9 240.3
Net margin -403.24% -174.15% -101.01% -109.04% -24.08% -24.08% -11.37% 8%
EPS 2 -8.110 -7.460 -7.200 -9.300 -3.520 -3.535 -1.862 1.845
Free Cash Flow 1 -418.6 -685.3 -718.1 -613.3 41.94 -317.6 -9.1 686.9
FCF margin -190.48% -139.05% -85.05% -59.12% 2.29% -16.97% -0.4% 22.86%
FCF Conversion (EBITDA) - - - - - - - 89.14%
FCF Conversion (Net income) - - - - - - - 285.85%
Dividend per Share 2 - - - - - - - -
Announcement Date 06/02/20 11/02/21 10/02/22 23/02/23 15/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 258.5 213.3 224.8 264.3 335 319.3 318.8 750.5 439.7 494.3 444.8 459.2 471.1 489.6 512.7
EBITDA 1 -183.2 -137.3 -181.6 -247.4 -174.3 -135.7 -216.7 227.2 - -29.92 -114.5 -79.7 -56.9 - -
EBIT 1 -194.6 -146.7 -191.7 -258 -188.6 -149.8 -229.8 213.9 -116.4 -43.44 -118.2 -113 -110.1 -129.4 -135.9
Operating Margin -75.26% -68.8% -85.26% -97.63% -56.3% -46.92% -72.1% 28.5% -26.47% -8.79% -26.58% -24.61% -23.37% -26.42% -26.51%
Earnings before Tax (EBT) 1 -260.3 -239.4 -274.7 -405.9 -207 -172.4 -274.2 150.7 -137.7 -63.59 -138 -138.6 -137.3 -150.5 -162.7
Net income 1 -258.5 -240.3 -277.4 -405.9 -207.5 -174.1 -276 147.8 -137.9 -65.94 -139.5 -136.9 -124.5 -152.3 -164.6
Net margin -99.97% -112.7% -123.39% -153.58% -61.93% -54.53% -86.59% 19.69% -31.35% -13.34% -31.36% -29.8% -26.44% -31.11% -32.11%
EPS 2 -2.160 -2.000 -2.290 -3.320 -1.680 -1.400 -2.210 1.180 -1.100 -0.5200 -1.113 -1.063 -0.9718 -1.052 -1.020
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 10/02/22 28/04/22 28/07/22 27/10/22 23/02/23 04/05/23 03/08/23 02/11/23 15/02/24 02/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 547 1,683 1,760 1,105 41.4 1,262 475 1,478
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -419 -685 -718 -613 41.9 -318 -9.1 687
ROE (net income / shareholders' equity) -53.4% -69.9% -106% -526% - -551% -65.2% 78.7%
ROA (Net income/ Total Assets) -44.6% -29.6% -24.2% -31.5% -11.9% -5.5% -5.12% -0.12%
Assets 1 1,985 2,901 3,525 3,595 3,688 8,197 5,018 -204,509
Book Value Per Share 2 12.80 8.730 4.890 -1.280 -1.750 -1.250 -2.090 0.6400
Cash Flow per Share 2 - -5.350 -5.420 -4.450 0.8300 -0.9500 2.830 5.910
Capex 1 140 70.4 76.4 72.1 62.2 66.2 86.8 120
Capex / Sales 63.78% 14.28% 9.05% 6.95% 3.4% 3.54% 3.84% 4%
Announcement Date 06/02/20 11/02/21 10/02/22 23/02/23 15/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
149.6 USD
Average target price
220.4 USD
Spread / Average Target
+47.30%
Consensus
  1. Stock Market
  2. Equities
  3. ALNY Stock
  4. Financials Alnylam Pharmaceuticals, Inc.